Vanda Pharmaceuticals financials
$5.03−2.71%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50.5M | $51.7M | $57.2M | $56.3M | $52.6M | $50.0M | $53.2M | $47.7M | $50.5M | $47.5M | $45.3M | $38.8M |
| Gross profit | $47.0M | $48.6M | $53.4M | $53.3M | $49.9M | $46.5M | $50.6M | $45.1M | $47.7M | $44.0M | $41.8M | $35.8M |
| Gross margin | 93.0% | 93.9% | 93.3% | 94.7% | 94.8% | 93.0% | 95.1% | 94.6% | 94.6% | 92.8% | 92.4% | 92.1% |
| Operating income | -$63.8M | -$50.2M | -$40.4M | -$31.3M | -$38.5M | -$41.0M | -$10.3M | -$11.0M | -$10.1M | -$9.2M | -$7.1M | -$6.0M |
| Net income | -$62.5M | -$48.6M | -$141.2M | -$22.6M | -$27.2M | -$29.5M | -$4.9M | -$5.3M | -$4.5M | -$4.1M | -$2.4M | $137.0K |
| Net margin | −123.7% | −93.9% | −246.8% | −40.1% | −51.7% | −58.9% | −9.2% | −11.2% | −9.0% | −8.7% | −5.3% | 0.4% |
| Diluted EPS | $-1.04 | $-0.82 | $-2.39 | $-0.38 | $-0.46 | $-0.50 | $-0.08 | $-0.09 | $-0.08 | $-0.07 | $-0.04 | $0.00 |
| EBITDA | -$61.6M | -$48.0M | -$38.3M | -$29.2M | -$36.5M | -$39.0M | -$8.3M | -$9.0M | -$8.2M | -$7.0M | -$7.1M | -$5.4M |
| Operating cash flow | -$31.1M | -$50.2M | -$29.4M | -$31.6M | -$15.3M | -$33.1M | -$1.8M | -$14.6M | -$6.9M | $7.6M | -$3.7M | -$2.0M |
| Free cash flow | -$31.3M | -$50.4M | -$29.5M | -$31.8M | -$15.6M | -$33.6M | -$2.0M | -$14.7M | -$7.0M | $7.6M | -$104.7M | -$2.1M |
| Diluted shares | 60.2M | 59.5M | 59.1M | 59.1M | 59.0M | 58.5M | 58.4M | 58.3M | 58.2M | 57.8M | 57.7M | 57.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $55.9M | $54.0M | $84.9M | $70.0M | $81.0M | $111.8M |
| Short-term investments | $114.1M | $148.3M | $179.0M | $223.7M | $244.6M | $229.1M |
| Total debt | $3.2M | $3.8M | $4.1M | $2.8M | $3.1M | $2.9M |
| Total assets | $412.5M | $433.5M | $488.9M | $601.1M | $624.7M | $631.9M |
| Total liabilities | $192.3M | $152.8M | $161.8M | $135.1M | $138.4M | $120.5M |
| Shareholders' equity | $220.2M | $280.8M | $327.2M | $466.0M | $486.3M | $511.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology